SCHEMBL6491695

SCHEMBL6491695

CCOC(=O)CCCOc1cc(C)c(NC(C)=O)c(N)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.48
PTPRB P23467 1/20 0.48
HSD17B10 Q99714 1/20 0.48
BRD4 O60885 1/20 0.45
PDK2 Q15119 2/20 0.40
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
P2RY12 Q9H244 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MCL1 Q07820 2/20 0.39
NLRP3 Q96P20 1/20 0.39
LTA4H P09960 2/20 0.38
CYSLTR2 Q9NS75 2/20 0.38
CYSLTR1 Q9Y271 2/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6497458 0.82 BRD4 (0.50) BRD4PDK2PDE3BPDE3AP2RY12
SCHEMBL6487855 0.81 MAPT (0.45) HPGDPTPRBHSD17B10BRD4TDP1
Hydrochloric Acid SCHEMBL6487897 0.80 BRD4 (0.49) BRD4PDK2PDE3BPDE3AP2RY12
SCHEMBL6498642 0.76 DHFR (0.42) PDK2TDP1L3MBTL1NLRP3LTA4H
SCHEMBL25505702 0.74 LMNA (0.65) HPGDBRD4TDP1LTA4HCYSLTR2
SCHEMBL6495773 0.73 HSD17B10 (0.49) HPGDPTPRBHSD17B10TDP1MAPT
SCHEMBL4389091 0.72 BRD4 (0.53) BRD4PDK2PDE3BPDE3AP2RY12
SCHEMBL6493050 0.72 ALOX15 (0.47) HPGDPTPRBHSD17B10TDP1CYP1A2
SCHEMBL6491379 0.72 BRD4 (0.42) BRD4PDK2PDE3BPDE3AP2RY12
SCHEMBL8409294 0.72 BRD4 (0.45) BRD4PDK2LTA4HCYSLTR2CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD HPGD 2381/4885PTPRB 1163/4885HSD17B10 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.